LCL

EBV-transformed B cells

Cell Type:
B cell
Tissue Origin:
blood
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
V O-017 10-30% high Plasmid (general) µg 100 µl I/II/2b
V T-020 25-38% low viability Plasmid (general) µg 100 µl I/II/2b

Citations (18)

Categories:
Transfection 
Authors:
Siegner SM, Ugalde L, Clemens A, Garcia-Garcia L, Bueren JA, Rio P, Karasu ME, Corn JE. 
In:
Nat Commun. (2022) 13(1): 6900 
Categories:
Transfection 
Authors:
Satish Kumar , Joanne E Curran , Erika C Espinosa , David C Glahn , John Blangero  
In:
J Bio Med Opt (2020) 7(1): 124 
Categories:
Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Jiang S, Wang LW, Walsh MJ, Trudeau SJ, Gerdt C, Zhao B, Gewurz BE. 
In:
Curr Biol (2018) 121: 31 
Categories:
Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Jiang S, Wang LW, Walsh MJ, Trudeau SJ, Gerdt C, Zhao B, Gewurz BE. 
In:
(2018) 121: 31 
Categories:
Transfection 
Authors:
Thomas SM, Kagan C, Pavlovic BJ, Burnett J, Patterson K, Pritchard JK, Gilad Y 
In:
PLoS Genet (2015) 11(5): e1005216 
Categories:
Transfection 
Authors:
Deepika Rajesh, Sarah J. Dickerson, Junying Yu, Matthew E. Brown, James A. Thomson, and Nicholas J. Seay 
In:
Blood (2011) 118 (7): 1797-1800 
Categories:
Transfection 
Authors:
Farfsing A, Engel F, Seiffert M, Hartmann E, Ott G, Rosenwald A, Stilgenbauer S, Döhner H, Boutros M, Lichter P, Pscherer A. 
In:
Leukemia (2009) 23(11): 2018-26 
Categories:
Transfection 
Authors:
Le Clorennec C, Ouk TS, Youlyouz-Marfak I, Panteix S, Martin CC, Rastelli J, Adriaenssens E, Zimber-Strobl U, Coll J, Feuillard J, Jayat-Vignoles C 
In:
J Virol (2008) 82(13): 6721-33 
Categories:
Transfection 
Authors:
Mancao C, Hammerschmidt W 
In:
Blood (2007) 110(10): 3715-21 
Categories:
Transfection 
Authors:
Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC 
In:
J Virol (2007) 81(14): 7363-70 
Categories:
Transfection 
Authors:
Lu KT, Sinquett FL, Dryer RL, Song C, Covey LR 
In:
Blood (2006) 108(12): 3769-76 
Categories:
Transfection 
Authors:
Stewart DR, Dombroski B, Urbanek M, Ankener W, Ewens KG, Wood JR, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS 
In:
J Clin Endocrinol Metab (2006) 91(10): 4112-4117 
Categories:
Transfection 
Authors:
Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB 
In:
J Immunol (2006) 177(6): 3746-56 
Categories:
Transfection 
Authors:
Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, Bond G and Levine AJ 
In:
Proc Natl Acad Sci USA (2005) 102(45): 16297-16302 
Categories:
Transfection 
Authors:
Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ and Kenney SC 
In:
J Virol (2005) 79(22): 13984-13992 
Categories:
Transfection 
Authors:
Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E and Kenney SC 
In:
J Virol (2005) 79(22): 13993-14003 
Categories:
Transfection 
Authors:
Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T and Shiku H 
In:
Clin Cancer Res (2005) 11(15): 5581-5589 
Categories:
Transfection 
Authors:
Hong GK, Delecluse HJ, Gruffat H, Morrison TE, Feng WH, Sergeant A and Kenney SC 
In:
J Virol (2004) 78(10): 4983-4992 
+ Show All